AAPL, SFAZ & Extended Watchlist

Apple, Inc. AAPL

As most of you will remember, we began tracking Apple Options on Monday this week. Our selection of the $415 Calls, which were trading as low as 6.55 at the time, yielded us gains of up to 405% as the 415′s touched 33.10 yesterday. Our look at the $420 Calls was good for as much as a 587% gain, after running from Monday’s low of 4.15 to yesterday’s high of 28.50.

As we stated on Wednesday, we were looking to push our strike price closer to the money as the surge in AAPL stock’s price continued, “looking at the $445, $450, and possibly even the $455 Calls.” Wednesday the $445′s were as cheap as 1.21, before running up to yesterday’s high of 5.03, a gain of 316%

As we’ve stated previously, Fridays are our favorite days to trade options. The closer we get to the end-of-day on Friday, the more the premium evaporates through time decay.

Apple Options yielded us the possibility for cumulative gains on the order of 1308% this week, and successfully illustrated that under the right conditions, savvy options-trading can be incredibly lucrative.

Safe Technologies International, Inc. SFAZ

SFAZ first appeared in our reports as part of our extended watchlist on January 4th. On that day, we saw the stock run from .008 up .014, for a one day run of 75%

Following our most recent alert on February 22nd, the stock ran 263% from .008-.029. Since that time, the stock basically flatlined, as it pulled all the way back to find support in the .002′s. In recent days, it has begun to pick its head up a bit, setting off our scanners and giving us due cause to monitor this stock into next week.

Extended Watchlist:

SFAZ, Options Trading & Extended Watchlist

Options Trading
We dabble in options trading from time to time, and want to remind our readers that this is not for the faint of heart. These ideas are meant for day-trading opportunities, and we can’t stress enough that it should be considered very high risk. That being said, we’d still like to share our current thoughts on the subject.

It appears as if the markets want to open up with an uptrend today. We’ve seen the biggest losses of the year for the past two days running. While uncertain as to whether that pullback to continue, at least from where we stand now, it appears that the markets want to rebound. In the event of an overall uptrend today, we are going to be focusing specifically on the weekly SPY Calls, and VXX Puts.

On the flip-side, if we continue to see more of this recent sell-off, we will obviously be reversing our strategy to focus mainly on the SPY Puts, and VXX Calls, as the two indices tend to move inversely to one another. At any rate, we want to stay close to the money, and have our strike price be pushed in the money. For example, the SPY is currently trading at 151.32 pre-market, so we are currently looking at the 151.00 Weekly SPY Calls.

Safe Technologies International, Inc. SFAZ

We first alerted SFAZ via our extended watchlist on January 4th. On that day, we saw the stock run from .008 up .014, for a one day pop of 75%

After mostly trading sideways since that initial run, the stock has now found a solid level of support at .002. Chart conditions are beginning to come across as favorable once again, as we’ve pointed out below.

Accumulation & Distribution have been on a steady rise, even as the stock has been feeling out a bottom. The RSI continues to hold above the 50MA overlay and looks like it’s beginning to push the 50-line. We appear to be at a pivot point with regard to resistance, the 50 and 20DMA’s at .0026, and .0028, respectively. Meanwhile, the blue bars on the MACD histogram are about to flip up topside as we are about to see a bullish cross, and the Slow STO recently passed above the 50MA overlay.


Extended Watchlist:

FOLD, MWIP & Extended Watchlist

FOLD caught our attention yesterday as an intriguing pharmaceutical play that recently underwent some panic selling, and is now coming off of the resultant bottom.First a little back-story: Amicus has been teamed up with pharma giant, GlaxoSmithKline (GSK), running clinical trials on a drug called migalastat HCI, meant to treat a rare disease in which a genetic mutation prevents enzymes from breaking down a fatty substance referred to as GL-3. As a result, GL-3 build up in the kidneys can lead to organ failure and death.

The big sell-off occurred back in late December when the duo announced that the study, statistically, failed to meet their objectives after a 6 month period, making a fast-track to FDA approval an impossibility.

The encouraging news, and the reason we think now is a prime time to take a look at FOLD, is that the studies do not conclude at the 6 month point; they have continued, and the 12 month results are expected to come early in 2013. While failing to meet project goals, there was still a 50% reduction in GL-3 buildup in 41% of the migalastat HCI group, as compared to just 28% of the placebo group. The 12-month results will be accompanied by the company meeting FDA officials to discuss the track to approval, and how it is altered by the results of trials still underway.

John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 9, 2013 at 3:00 p.m. PT. which can be viewed via a LIVE WEBCAST on the specified date and time.

What really jumps out to us, is simply the fact that FOLD recently saw a big gap down, and has now begun to recover. Often in the past we’ve seen cases such as this where the stock bounces back to fill the gap, offering up great opportunities for gain.

It could also come to that sooner, rather than later- The company also has other irons in the fire, as this morning it released a PR regarding another of its drugs currently in testing phases, this time with positive results:

Amicus Therapeutics Announces Positive Results From All Four Cohorts in Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease

CRANBURY, N.J., Jan 04, 2013 (GLOBE NEWSWIRE via COMTEX) — Strong Proof-of-Concept Data for Chaperone’s Ability to Stabilize and Enhance Activity and Uptake of Currently Marketed ERT Products for Pompe Disease

Results to be Presented at LDN WORLD Symposium in February 2013

Initiation of Repeat-Dose Pompe Study Anticipated in 3Q13

Amicus Therapeutics (Nasdaq: FOLD) today announced positive preliminary results from all 4 dose cohorts in a Phase 2 study (Study 010) to evaluate the safety and pharmacokinetic (PK) effects of the pharmacological chaperone AT2220 (duvoglustat HCl) co-administered with enzyme replacement therapy (ERT) for Pompe disease (Myozyme and Lumizyme). Myozyme and Lumizyme (alglucosidase alfa, or recombinant human GAA enzyme, rhGAA) are the first and only approved treatments for Pompe disease.


We will be continuing to follow this play, and keep everyone updated as more details arise.


MediSwipe, Inc. MWIP

A lot of you may have missed our last report before the holidays, in which we mentioned that we would like to see MWIP continue to hold support above a penny and test its previous highs. Yesterday saw the stock break past its previous high of .0199 into blue-sky territory, hitting a high of .0289, earning us a spot on the Penny Stock Rumble with a gain of 50%

In total, from the low following our first mention of MWIP back at .0024, yesterday’s high marks an astonishing 1104% gain.

If and when we see a pullback on MWIP, we want to see the previous resistance of .0199 hold as a future level of support for us to remain bullish.


Extended Watchlist: